Skip to main content

Aroa Soriano Fernández

Institutions of which they are part

Main researcher
Childhood Cancer and Blood Disorders
Vall Hebron Institut de Recerca

Aroa Soriano Fernández

Institutions of which they are part

Main researcher
Childhood Cancer and Blood Disorders
Vall Hebron Institut de Recerca

Projects

JARC: Joint Action on Rare Cancers Grant Agreement: 724161 VHIR involved in WP9 Task 2 : Objective Use of relevant paediatric preclinical models (patients derived xenografts, genetically modified models, other preclinical model) for experimental

IP: Miguel Segura Ginard
Collaborators: Soledad Gallego Melcón, Aroa Soriano Fernández, Josep Roma Castanyer
Funding agency: Ex. Agency for Health Consumers (EAHC)-CHAFEA
Funding: 6959.28
Reference: JARC_3HP-CHAFEA2015
Duration: 01/10/2016 - 30/09/2019

Investigació translacional en càncer infantil (GRE)

IP: Josep Sánchez de Toledo Codina
Collaborators: Soledad Gallego Melcón, Aroa Soriano Fernández, Maria Cristina Díaz de Heredia Rubio, Miguel Segura Ginard, Anna Llort Sales, Raquel Hladun Alvaro, Laura Alonso Garcia, Josep Roma Castanyer
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 30000
Reference: 2014 SGR 660
Duration: 01/01/2014 - 31/12/2016

Nanoterapia basada en microRNAs: nuevo tratamiento para tumores pediátricos del sistema nervioso

IP: Miguel Segura Ginard
Collaborators: Luís Gros Subias, Aroa Soriano Fernández, Josep Sánchez de Toledo Codina, Constantino Sábado Álvarez
Funding agency: Instituto de Salud Carlos III
Funding: 116765
Reference: PI14/00561
Duration: 01/01/2015 - 31/12/2017

TERAPIA PERSONALIZADA CONTRA ERK5 EN NEUROBLASTOMA

IP: Aroa Soriano Fernández
Collaborators: Soledad Gallego Melcón, Miguel Segura Ginard
Funding agency: Asociación Española Contra el Cáncer
Funding: 20000
Reference: 2014/AECC-JB/SORIANO
Duration: 31/01/2015 - 31/01/2017

Related news

The initiative will enable young people aged 12 to 18 to collaborate with campus researchers in the design, development and communication of scientific projects, placing patients and families at the centre of the research process.

The REACH5 study confirms that the efficacy and safety results observed in previous studies are maintained after three years of follow-up.

In-depth knowledge of tumours helps identify specific alterations and enables the provision of targeted therapies for each patient.

Related professionals

Sandra Vilaró Miranda

Sandra Vilaró Miranda

Research assistant
Shock, Organ Dysfunction and Resuscitation
Read more
Susana González Suárez

Susana González Suárez

Postdoctoral researcher
Cardiovascular Diseases
Read more
Rafael Garcia Merida

Rafael Garcia Merida

Administration and Management
Clinical Neuroimmunology
Read more
Eugenio Andres Aliaga Martinez

Eugenio Andres Aliaga Martinez

Postdoctoral researcher
Reconstructive Surgery of the Locomotor System
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.